Comparison of efficacy and adverse reactions of Vonoprazan fumarate tablets and pantoprazole sodium enteric-coated tablets in the treatment of reflux esophagitis
Comparison of efficacy and adverse reactions of Vonoprazan fumarate tablets and pantoprazole sodium enteric-coated tablets in the treatment of reflux esophagitis
Objective To explore the efficacy and adverse reactions of Vonoprazan fumarate tablets(abbreviated as Vonoprazan)and pantoprazole sodium enteric-coated tablets(abbreviated as pantoprazole)in the treatment of reflux esophagitis(RE).Methods A total of 114 RE patients admitted to Chongming Hospital Affiliated to Shanghai University of Medicine and Health Sciences from June 2020 to June 2022 were prospectively included in this study.They were divided into group A and group B,each with 57 cases,using the random number table method.Group A was treated with Vonoprazan,and group B was treated with pantoprazole.The efficacy,symptom scores,levels of gastrointestinal hormones,the level of inflammation and adverse reactions were compared between the two groups.Results The curative effect of the group A was better than that of the group B(P＜0.05).The differences of the Reflux Disease Questionnaire scores,Gastroesophageal Reflux Disease Questionnaire scores,and levels of vasoactive intestinal peptide,cholecystokinin,interleukin-8,inducible nitric oxide synthase,nuclear factor-κB,gastrin,motilin and interleukin-10 before and after the treatment in the group A were higher than those in the group B(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).The recurrence rate of the group A was lower than that of the group B(P＜0.05).Conclusion Compared with pantoprazole,Vonoprazan demonstrates superior therapeutic effects in the clinical treatment of RE,showing better improvement in symptoms and levels of gastrointestinal hormones and inflammatory factors,lower recurrence rate,and fewer safety concerns.
维普
万方数据